Compare Fox Corp Class B (FOX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Novartis AG — how do they compare? Fox Corp Class B trades at $56.83 (market cap $25.36B), while Novartis AG trades at $143.3 (market cap $268.57B). The key difference: Novartis AG is far larger — about 10.6× Fox Corp Class B's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Novartis AG for 82 Days on average.
| FOX | NVS | |
|---|---|---|
Market Cap | $25.36B | $268.57B |
Volume | 886,620 | 1,532,573 |
Sector | Media | Health |
52-Week High | $67.76 | $168.62 |
52-Week Low | $44.39 | $121.80 |
Typical Hold Time | 75 Days | 82 Days |
Enterprise Value | $28.72B | $309.89B |
Dividend Yield | 1.02% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.79 surpassing the $1.44 expectation. Revenue grew to $16.30B in 2025, and net income margin expanded to 13.88%. The company maintains solid cash flow, with operating cash flow of $3.32B in 2025. A dividend of $0.29 is scheduled for payment on September 23, 2026.
The stock presents a value opportunity with a P/E of 14.85 below industry averages, supported by analyst consensus price target of $84.75 implying 51% upside. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical indicators. Investor sentiment is mixed amid ongoing regulatory scrutiny of acquisitions, as noted in recent news.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
